MEETING ABSTRACT





Serrated polyposis syndrome and colonoscopic surveillance: who is it safe to follow?

S Parry^{1,2*}, S Woodall¹, G Willdridge¹, MD Walsh³, DD Buchanan³, C Rosty^{4,5}, JP Young^{3,5}

From Familial Aspects of Cancer 2011 Research and Practice: A combined meeting of kConFab, Australian Breast Cancer Family Study, Australian Colorectal Cancer Family Study, Australian Ovarian Cancer Study, Family Cancer Clinics of Australia and New Zealand and kConFab Kingscliff, Australia. 23-26 August 2011

Aim

To assess colorectal cancer (CRC) risk during colonoscopy surveillance in a cohort of patients with the serrated polyposis syndrome (SPS).


Method

Colonoscopy and histology records from January 2000 to time of interview for 67 New Zealand patients, meeting WHO criteria for a diagnosis of SPS and enrolled in the Genetics of Serrated Neoplasia study, were reviewed. Polyp demographics, smoking status and family history of cancer were recorded.

Results

Of 67 patients 18 presented with CRC (mean age 57yrs, 12 Female). Only one of 18 reported a first degree relative (FDR) with CRC. Over a median follow-up of 8 years from time of surgery with an average interval of 16 months between colonoscopies, two patients developed metachronous CRC: one identified at prophylactic completion colectomy and one in association with first diagnosis of SPS 19 yrs following initial CRC and 30 months after a previous colonoscopy. Of 45 patients with polyps alone (mean age 48 yrs, 27 female) followed for a median of 9 years with an average interval of 15 months between colonoscopies, none developed CRC despite 33 having multiple pan colonic polyps. Of these 33, 70% had an adenoma, 18 % a sessile serrated polyp and 53 % polyps >10 mm. A FDR with CRC was reported in 14/45 (31%). Four patients with multiple pan colonic polyps and no FDR with CRC underwent prophylactic subtotal colectomy (mean age 58 yrs, 3

¹New Zealand Familial Gastrointestinal Cancer Registry, Auckland Hospital, New Zealand



Conclusion

If endoscopic control is feasible, SPS patients can be judiciously managed by frequent surveillance colonoscopy.

Author details

¹New Zealand Familial Gastrointestinal Cancer Registry, Auckland Hospital, New Zealand. ²Department of Gastroenterology, Middlemore Hospital, Auckland, New Zealand. ³Familial Cancer Laboratory, QIMR, Herston, Queensland, Australia. ⁴Department of Molecular and Cellular Pathology, University of Queensland, Queensland, Australia. ⁵School of Medicine, University of Queensland, Herston, Queensland, Australia.

Published: 12 April 2012

doi:10.1186/1897-4287-10-S2-A20

Cite this article as: Parry *et al.*: Serrated polyposis syndrome and colonoscopic surveillance: who is it safe to follow? *Hereditary Cancer in Clinical Practice* 2012 **10**(Suppl 2):A20.



© 2012 Parry et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Full list of author information is available at the end of the article